118026-14-5

Basic information

• Product Name: 6-METHYL-N,N-DIMETHYL-2-(4-METHYLPHENYL)-2-HYDROXYIMIDAZO[1,2-ALPHA]PYRIDINE-3-ACETAMIDE
• Synonyms: 6-METHYL-N,N-DIMETHYL-2-(4-METHYLPHENYL)-2-HYDROXYIMIDAZO[1,2-A]PYRIDINE-3-ACETAMIDE;6-METHYL-N,N-DIMETHYL-2-(4-METHYLPHENYL)-2-HYDROXYIMIDAZO[1,2-ALPHA]PYRIDINE-3-ACETAMIDE;IMidazo[1,2-a]pyridine-3-acetaMide, a-hydroxy-N,N,6-triMethyl-2-(4-Methylphenyl)-
• CAS NO: 118026-14-5
• Molecular Formula: C₁₉H₂₁N₃O₂
• Molecular Weight: 324.39688
• Mol File: 118026-14-5.mol
• Article Data: 8

Chemical Properties

• Melting Point: 175-177 °C
• Appearance: /
• Density: 1.19±0.1 g/cm3(Predicted)
• PKA: 12.04±0.20(Predicted)
• CAS DataBase Reference: 6-METHYL-N,N-DIMETHYL-2-(4-METHYLPHENYL)-2-HYDROXYIMIDAZO[1,2-ALPHA]PYRIDINE-3-ACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-METHYL-N,N-DIMETHYL-2-(4-METHYLPHENYL)-2-HYDROXYIMIDAZO[1,2-ALPHA]PYRIDINE-3-ACETAMIDE(118026-14-5)
• EPA Substance Registry System: 6-METHYL-N,N-DIMETHYL-2-(4-METHYLPHENYL)-2-HYDROXYIMIDAZO[1,2-ALPHA]PYRIDINE-3-ACETAMIDE(118026-14-5)

Safety Data

• Hazardous Substances Data: 118026-14-5(Hazardous Substances Data)

Usage

Description

6-METHYL-N,N-DIMETHYL-2-(4-METHYLPHENYL)-2-HYDROXYIMIDAZO[1,2-ALPHA]PYRIDINE-3-ACETAMIDE is a chemical compound with a complex structure, featuring a methyl group, dimethyl groups, a hydroxyl group, and an imidazo[1,2-alpha]pyridine core. It is characterized by its unique molecular arrangement and functional groups, which may contribute to its potential applications in various fields.

Uses

Used in Pharmaceutical Industry:
6-METHYL-N,N-DIMETHYL-2-(4-METHYLPHENYL)-2-HYDROXYIMIDAZO[1,2-ALPHA]PYRIDINE-3-ACETAMIDE is used as an impurity in the synthesis of Zolpidem (Z650000), a selective non-benzodiazepine GABAA receptor agonist. It serves as a sedative and hypnotic agent, helping to induce sleep and treat insomnia. As a controlled substance, it is regulated due to its potential depressant effects.

Upstream product

• 79036-50-3 N,N-dimethyl-2-oxoethanamide 
• 88965-00-8 6-methyl-2-(4-methyl-phenyl)-imidazo[1,2-a]pyridine 
• 722553-24-4 α-hydroxy-zolpidem-O-acetate 
• 722553-25-5 α-hydroxy-zolpidem-O-propionate 
• 82626-48-0 N,N,6-trimethyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-acetamide 
• 25408-61-1 Ν,Ν-dimethylacetamide dimethyl acetal 
• 1603-41-4 (5-methyl-pyridin-2-yl)amine 
• 619-41-0 4-(bromoacetyl)toluene 

Downstream Products

• 82626-48-0 N,N,6-trimethyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-acetamide 
• 722553-24-4 α-hydroxy-zolpidem-O-acetate 
• 722553-25-5 α-hydroxy-zolpidem-O-propionate 
• 118026-15-6 N,N,6-trimethyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-ylchloroacetamide hydrochloride 

Relevant articles and documents

Preparation method of zolpidem

The invention discloses a preparation method of a zolpidem intermediate. In the process of preparing the zolpidem intermediate N, N, 6-trimethyl-2-(4-methylphenyl)-imidazo [1, 2-alpha] pyridine-3-acetamide hydrochloride by reducing N, N, 6-trimethyl-2-(4-methylphenyl)-imidazo [1, 2-alpha] pyridine-3-acetamide hydrochloride, through process optimization and parameter adjustment, by using a 10% palladium-carbon catalyst and combining the reaction condition of hydrogen pressure of 0.02-0.09 MPa, the conversion effect of the N, N, 6-trimethyl-2-(4-methylphenyl)-imidazo [1, 2-alpha] pyridine-3-chloroacetamide hydrochloride is promoted, side reactions and impurities are reduced, the product yield is increased, the problem of low product synthesis yield in the process of preparing N, N, 6-trimethyl-2-(4-methylphenyl)-imidazo [1, 2-alpha] pyridine-3-acetamide hydrochloride through reduction reaction in zolpidem production is solved, and the production cost of zolpidem tartrate is reduced.

Study on a three-step rapid assembly of zolpidem and its fluorinated analogues employing microwave-assisted chemistry

We developed an efficient microwave-assisted three-step synthesis of zolpidem and its fluorinated analogues 1-3. The procedure relays on the utilization of easily accessible and inexpensive starting materials. Our protocol shows superior performance in terms of yield and purity of products, compared to conventional heating systems. Notably, the total time needed for reaction accomplishment is significantly lower comparing to oil bath heating systems. Finally, we have performed a detailed study on the preparation of zolpidem tartrate salt I, and we assessed its particle-sizes using a polarizing microscope. Our goal was to select the appropriate method that generates the acceptable particle-size, since the solid-size directly influences solubility in biological fluids and further bioavailability. We believe that the disclosed procedure will help to produce a lab-scale quantity of zolpidem and its fluorinated derivatives 1-3, as well as zolpidem tartrate salt I, with suitable fine-particle size for further biological experimentation.